Latest Updates: November 2023
- Patient exposure: Homepage
- Key safety topics: PML, CM, Reproductive toxicity, and COVID-19
As of 28th February 2023
**exposure includes both clinical trials and postmarketing experience; postmarketing patient exposure is estimated based on worldwide sales volume
As of 28th February 2023, exposure to fingolimod^ (any dose) by duration from Novartis MS clinical trials1
^Actual exposure to fingolimod (any dose) in clinical trials by duration